Cullinan Therapeutics Management

Management Kriterienprüfungen 2/4

Cullinan Therapeutics' CEO ist Nadim Ahmed , ernannt in Oct 2021, hat eine Amtszeit von 2.67 Jahren. Die jährliche Gesamtvergütung beträgt $4.01M , bestehend aus 16.2% Gehalt und 83.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.046% der Aktien des Unternehmens, im Wert von $499.32K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 1.3 Jahre.

Wichtige Informationen

Nadim Ahmed

Geschäftsführender

US$4.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	16.2%
Amtszeit als Geschäftsführer	2.7yrs
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.3yrs

Jüngste Management Updates

Recent updates

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Nadim Ahmed im Vergleich zu den Einnahmen von Cullinan Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$132m
Dec 31 2023	US$4m	US$649k	-US$153m
Sep 30 2023	n/a	n/a	-US$156m
Jun 30 2023	n/a	n/a	-US$142m
Mar 31 2023	n/a	n/a	US$65m
Dec 31 2022	US$4m	US$618k	US$111m
Sep 30 2022	n/a	n/a	US$105m
Jun 30 2022	n/a	n/a	US$113m
Mar 31 2022	n/a	n/a	-US$78m
Dec 31 2021	US$39m	US$125k	-US$66m

Vergütung im Vergleich zum Markt: NadimDie Gesamtvergütung ($USD4.01M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD3.40M).

Entschädigung vs. Einkommen: NadimDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Nadim Ahmed (56 yo)

2.7yrs

Amtszeit

US$4,008,206

Vergütung

Mr. Nadim Ahmed has been a President, Chief Executive Officer and Director of Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since October 18, 2021. He joined Cullinan Therapeutics...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Nadim Ahmed	President	2.7yrs	US$4.01m	0.046% $ 441.3k
Jeffrey Jones	Chief Medical Officer	2.3yrs	US$2.42m	0.024% $ 230.1k
Patrick Baeuerle	Co-Founder	no data	US$1.96m	0.61% $ 5.9m
Mary Fenton	Chief Financial Officer	less than a year	keine Daten	keine Daten
Jennifer Michaelson	Chief Scientific Officer	less than a year	keine Daten	0.068% $ 659.8k
Jacquelyn Sumer	Chief Legal Officer	1.8yrs	keine Daten	0.017% $ 165.8k
Rose Weldon	Senior Vice President of Communications	2.4yrs	keine Daten	keine Daten
Steve Andre	Chief Human Resources Officer	2.4yrs	keine Daten	keine Daten
Corinne Savill	Chief Business Officer	7.3yrs	keine Daten	0.25% $ 2.4m
Kevin Johnston	Chief Technical Operations Officer	2.4yrs	keine Daten	keine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: CGEMDas Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Nadim Ahmed	President	2.7yrs	US$4.01m	0.046% $ 441.3k
Patrick Baeuerle	Co-Founder	less than a year	US$1.96m	0.61% $ 5.9m
Thomas Ebeling	Independent Director	6.8yrs	US$220.20k	0.32% $ 3.1m
Stephen Webster	Independent Director	3.8yrs	US$232.24k	0% $ 0
Anthony Rosenberg	Independent Chairman of the Board	6.8yrs	US$284.84k	0.078% $ 756.5k
Ronald Levy	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Anthony Tolcher	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Bahija Jallal	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
Anne-Marie Martin	Independent Director	2.3yrs	US$164.45k	0% $ 0
Patricia LoRusso	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten
David Ryan	Independent Director	1.6yrs	US$43.75k	0% $ 0
David McDermott	Member of Scientific Advisory Board	less than a year	keine Daten	keine Daten

1.3yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: CGEMDie Vorstandsmitglieder gelten nicht als erfahren ( 1.3 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Cullinan Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Independent Director exercised options to buy US$402k worth of stock.

Independent Director exercised options to buy US$2.4m worth of stock.

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Recent updates

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors

Investor sentiment improved over the past week

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology grants stock options for 125.7K shares

Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal Officer

Insider recently sold US$712k worth of stock

Chief Business Officer notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth Index

Insider recently sold US$1.3m worth of stock

Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

President recently bought US$100k worth of stock

Insider recently sold US$4.0m worth of stock

Price target decreased to US$39.25

Forecast to breakeven in 2022

Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.

Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology, Inc. to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio At American Association for Cancer Research 2022

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology, Inc. Announces Management Appointments

Price target decreased to US$47.75

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Cln-081 for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Strategic Advisor notifies of intention to sell stock

Cullinan Oncology, Inc. Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CFO & Treasurer exercised options and sold US$166k worth of stock

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Chief Development Officer of Biologics exercised options and sold US$81k worth of stock

CFO & Treasurer exercised options and sold US$363k worth of stock

Insider recently sold US$815k worth of stock

Chief Development Officer of Biologics notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider recently sold US$753k worth of stock

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Cullinan Oncology, Inc. Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

Cullinan Oncology, Inc. Receives Investigational New Drug Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML